Provider Learning Opportunities Join leading COPD experts to explore the role of type 2 inflammation and eosinophils in COPD. Learn how to individualize treatment using guideline-based care and gain confidence in integrating new biologic therapies to improve outcomes for patients with eosinophilic COPD. Learning Objectives: Summarize the new understanding of COPD disease onset, trajectory, and risk factors Explain the role of type 2 inflammation as a driver of the pathophysiology of COPD and lung remodeling for some people with difficult-to-control disease Describe the mechanism of action, efficacy, and safety of new biologic agents for COPD Discuss how to optimize the management of COPD by providing smoking-cessation counselling Access the program > Have an idea for a professional development experience? Email us at info@copdfoundation.org.
Join Us on COPD360social Join the Conversation Become a Member > Already a Member? Sign In to Participate >
This page was reviewed on February 17, 2026 by the COPD Foundation Content Review and Evaluation Committee.